LivaNova PLC
LIVN
NASDAQ·Healthcare·Medical - Devices·Mkt cap $4.5B
$81.63
▼ -0.94%
P/E
23.66
Mkt Cap
$4.5B
52-Wk Range
$48.82–$85.76
52-Week Range
$48.82 - $85.76
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 45.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary VNS Therapy technology with established clinical efficacy and regulatory approvals across multiple indications
- Integrated portfolio spanning surgical support and implantable neuromodulation devices, creating cross-selling opportunities
- Strong relationships with key opinion leaders and healthcare providers; direct sales force and distributor network
- Clinical validation through research partnerships (Verily collaboration) and ongoing VITARIA development for heart failure
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Expansion of VNS Therapy into new indications including heart failure treatment via VITARIA System
Value
Fairly valued vs Medical Devices peers
Momentum
Strong
+15.5% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying LIVN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 5, 2026
Reported EPS of $1.26 vs $1.09 consensus (+15.6% surprise). Revenue of $390.6M vs $380.5M expected (+2.6%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+15.6%
Revenue trend · last 8Q
—
+4%
+7%
+11%
+12%
+12%
+14%
+11%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$318.1M
$321.8M
$316.9M
$352.5M
$357.8M
$360.9M
$362.3M
$390.5M
Margins · last 8Q
Gross
69.8%
Operating
9.9%
Profit
27.8%
Wall Street consensus
6 analysts · 83% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
83%
Hold
17%
Sell
0%
Median Price Target
—
Latest: Piper Sandler · Sep 2, 2026
vs Industry
How LIVN stacks vs Medical - Devices
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related